ATARAX

Main information

  • Trade name:
  • ATARAX 2 mg/ ml syrup
  • Dosage:
  • 2 mg/ ml
  • Pharmaceutical form:
  • syrup
  • Prescription type:
  • Prescription only
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • ATARAX 2 mg/ml syrup
    Finland
  • Language:
  • English

Therapeutic information

  • Therapeutic area:
  • Hydroxyzine
  • Product summary:
  • ; Suitability for use in older adult patients Hydroxyzini hydrochloridum Avoid using in older persons. Anticholinergic. Sedative. Risk of QT prolongation. A long-acting. Do not use as a hypnotic or sedative. Reduce the dose in renal insufficiency. Significant adverse effects include dizziness, tachycardia, confusion and cognitive disorder. Increases risk for falls. Weakens the efficacy of anti-Alzheimer´s drugs.

Status

  • Source:
  • Fimea
  • Authorization status:
  • Marketing authorization granted
  • Authorization number:
  • 5794
  • Authorization date:
  • 30-10-2006
  • Last update:
  • 26-07-2018